Here's a snapshot of first-quarter financial results for ASC-relevant gastroenterology and supply companies:
CRH Medical posted revenues of $29.1 million for the first quarter of 2019.
Exact Sciences posted first-quarter 2019 revenues of $162 million, a 79 percent year-over-year increase.
For the first quarter, Pacira BioSciences reported record sales of Exparel, a non-opioid pain management drug that became eligible for separate Medicare reimbursement in ASCs as of Jan. 1.
Specialty biopharmaceutical company EyePoint Pharmaceuticals reported $2 million in revenue for the first quarter of 2019, up from $928,000 year over year.